key: cord-0830044-m721p0td
authors: Atak, Mehmet Fatih; Farabi, Banu; Akbayrak, Atiye; Kalelioğlu, Mehmet Berati; Rao, Babar K.
title: Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with COVID‐19 without hydroxychloroquine use: Report of the first case
date: 2021-06-27
journal: J Cosmet Dermatol
DOI: 10.1111/jocd.14304
sha: 5e441925f04e77971f7eeb88faa8b25f91b09fab
doc_id: 830044
cord_uid: m721p0td

Favipiravir is an antiviral agent used in the treatment of COVID-19 infection, and related cutaneous adverse events are rare 1 . Acute generalized exanthematous pustulosis (AGEP) has been reported in COVID-19 patients, mostly associated with hydroxychloroquine (HCQ). There are few AGEP cases in COVID-19 patients reported due to β-lactam antibiotics 2,3 in the literature. Herein, we report the first case of favipiravir-induced AGEP with histologic findings.

Dr. Babar K. Rao is a consultant for Caliber ID (The manufacturer of VivaScope). The other authors have no conflict of interest to declare.

The patient in this manuscript have given written informed consent to the publication of his case details.

The authors confirm that the data supporting the findings of this study are available within the article. 

Favipiravir: a new and emerging antiviral option in COVID-19

Delayed presentation of acute generalized Exanthematous pustulosis following treatment with Cefepime in a patient with COVID-19 without the use of hydroxychloroquine

Severe adverse drug reaction in SARS-CoV-2 infection: AGEP induced by ceftriaxone and confirmed by patch test

Treatment of SARS-cov-2 pneumonia with favipiravir: Early results from the Ege University cohort

Isolated maculopapular eruption localized to head and neck: A cutaneous sign of COVID-19 infection

Acute generalized Exanthematous Pustulosis (AGEP) in 12 patients treated for SARS-CoV-2 positive pneumonia

Comment on "Psoriasis, COVID-19, and acute respiratory distress syndrome: Focusing on the risk of concomitant biological treatment